Toll-like receptor 9 agonists as cancer therapeutics

被引：53
|
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [11] Toll-like receptors involved in the response to microbial pathogens: Development of agonists for toll-like receptor 9
    Schetter, C
    Vollmer, J
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2004, 7 (02) : 204 - 210
  • [12] Trial Watch Experimental Toll-like receptor agonists for cancer therapy
    Galluzzi, Lorenzo
    Vacchelli, Erika
    Eggermont, Alexander
    Fridman, Wolf Herve
    Galon, Jerome
    Sautes-Fridman, Catherine
    Tartour, Eric
    Zitvogel, Laurence
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2012, 1 (05): : 699 - 716
  • [13] Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics
    Gomariz, Rosa P.
    Gutierrez-Canas, Irene
    Arranz, Alicia
    Carrion, Mar
    Juarranz, Yasmina
    Leceta, Javier
    Martinez, Carmen
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (09) : 1063 - 1080
  • [14] Radiotherapy and Toll-Like Receptor Agonists
    Marabelle, Aurelien
    Filatenkov, Alex
    Sagiv-Barfi, Idit
    Kohrt, Holbrook
    SEMINARS IN RADIATION ONCOLOGY, 2015, 25 (01) : 34 - 39
  • [15] Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice
    Gao, Wenyan
    Sun, Xiaodan
    Li, Danni
    Sun, Lin
    He, Yang
    Wei, Huanping
    Jin, Feng
    Cao, Yaming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 89
  • [16] The Biology of Toll-Like Receptor 9 and Its Role in Cancer
    Alzahrani, Badr
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2020, 30 (05): : 457 - 474
  • [17] Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
    Kirtland, Max E.
    Tsitoura, Daphne C.
    Durham, Stephen R.
    Shamji, Mohamed H.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [18] Potential of Toll-like receptor 9 agonists in combined anticancer immunotherapy strategies: synergy of PAMPs and DAMPs?
    Holtick, Udo
    Klein-Gonzalez, Nela
    von Bergwelt-Baildon, Michael S.
    IMMUNOTHERAPY, 2011, 3 (03) : 301 - 304
  • [19] Toll-Like Receptor Agonists as Adjuvants for HIV Vaccines
    Stevceva, L.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (33) : 5079 - 5082
  • [20] Anti-tumor Activity of Toll-Like Receptor 7 Agonists
    Chi, Huju
    Li, Chunman
    Zhao, Flora Sha
    Zhang, Li
    Ng, Tzi Bun
    Jin, Guangyi
    Sha, Ou
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345